EP0408284A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Amylin for treatment of bone disorders
Assignee: Amylin Pharmaceuticals LLC
•
Filing: 1990-07-09
•
Granted: —
•
Expires: 2010-07-09
Abstract
Abstract Use of amylin, or variants of amylin, as well as amylin agonists, for the treatment of bone disorders, in particular osteoporosis, Paget's disease, and malignant deposits in bone, bone loss of malignancy or endocrine disorders or autoimmune arthritides or immobility and disuse, and in other conditions where a hypocalcaemic effect is of benefit. Functional peptide fragments of amylin, or a variant of amylin or amylin fragment, are provided as well as a soluble amylin, amylin fragments, or variants thereof, or a lyophilized product, or an oral formulation for use alone, or in combination with other agents, including insulin (or insulin-stimulating agents, including but not limited to the sulfonylureas) and estrogens, for the treatment of disorders of bone or calcium balance.
Inventors
- 👤 Iain Macintyre
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 15:28
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K38/23; A61K38/28; A61P; A61P3/00; A61P3/02; A61P43/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
34 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for disorders of bone which are associated with excessive resorption or remodelling of bone tissue.
Claim 2
Dependent Claim
34 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for disorders of bone which are associated with excessive resorption or remodelling of bone tissue.
Claim 3
Dependent Claim
33 words
The amylin or amylin agonist according to claim 1 wherein said bone disorder is osteoporosis, Paget's disease; or bone loss from malignancy, endocrine disorders, autoimmune arthritides, breakage and fracture; or immobility and disuse.
Claim 4
Dependent Claim
20 words
The amylin or amylin agonist according to claim 1 or 2 wherein the method further comprises the administration of insulin.
Claim 5
Dependent Claim
17 words
The amylin or amylin agonist according to any one of the preceding claims which is substantially pure.
Claim 6
Dependent Claim
21 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for hypercalcaemia.
Claim 7
Dependent Claim
21 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for hypercalcaemia.
Claim 8
Dependent Claim
53 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for disorders of bone which are associated with relative or absolute hypoamylinemia, which method comprises the administration of a replacement amount of amylin or a therapeutically effective amount of amylin or an amylin agonist.
Claim 9
Dependent Claim
53 words
Amylin or an amylin agonist for use in a method for the treatment of the human or animal body for disorders of bone which are associated with relative or absolute hypoamylinemia, which method comprises the administration of a replacement amount of amylin or a therapeutically effective amount of amylin or an amylin agonist.
Claim 10
Independent Claim
42 words
A method for monitoring a patient undergoing any of the therapies defined in any one of claims 1, 2 or 5 or 6, which method comprises determination of the level of amylin in the blood, serum, plasma or urine of said patient.
Claim 11
Independent Claim
43 words
A method for monitoring the progression of a bone disorder associated with relative or absolute hypoamylinemia, which method comprises determination of the level of amylin in the blood, serum, plasma or urine of a patient having or suspected of having said bone disorder.
Claim 12
Independent Claim
43 words
A method for monitoring the progression of a bone disorder associated with relative or absolute hypoamylinemia, which method comprises determination of the level of amylin in the blood, serum, plasma or urine of a patient having or suspected of having said bone disorder.
Claim 13
Dependent Claim
47 words
The use of amylin or an amylin agonist in the manufacture of a medicament for the treatment of disorders of bone which are associated with excessive resorption or remodelling of bone tissue, or which are associated with relative or absolute hypoamylinemia or for the treatment of hypercalcaemia.
Claim 14
Dependent Claim
47 words
The use of amylin or an amylin agonist in the manufacture of a medicament for the treatment of disorders of bone which are associated with excessive resorption or remodelling of bone tissue, or which are associated with relative or absolute hypoamylinemia or for the treatment of hypercalcaemia.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.